BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 19743561)

  • 1. The NICE way of influencing health spending: a conversation with Sir Michael Rawlins. Interview by Nicholas Timmins.
    Rawlins M
    Health Aff (Millwood); 2009; 28(5):1360-5. PubMed ID: 19743561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Professor Sir Michael Rawlins--chairman of NICE. National Institute of Clinical Excellence. Interviewed by Sue Silver.
    Rawlins M
    Lancet Oncol; 2000 Oct; 1():113-7. PubMed ID: 11905663
    [No Abstract]   [Full Text] [Related]  

  • 3. From guidance to practice: Why NICE is not enough.
    Dent TH; Sadler M
    BMJ; 2002 Apr; 324(7341):842-5. PubMed ID: 11934781
    [No Abstract]   [Full Text] [Related]  

  • 4. NICE work--providing guidance to the British National Health Service.
    Rawlins MD
    N Engl J Med; 2004 Sep; 351(14):1383-5. PubMed ID: 15459297
    [No Abstract]   [Full Text] [Related]  

  • 5. Reallocating resources: how should the National Institute for Health and Clinical Excellence guide disinvestment efforts in the National Health Service?
    Pearson S; Littlejohns P
    J Health Serv Res Policy; 2007 Jul; 12(3):160-5. PubMed ID: 17716419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introducing the National Institute for Health and Clinical Excellence.
    Jaques H
    Eur Heart J; 2012 Sep; 33(17):2111-2. PubMed ID: 23106069
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality, innovation, and value for money: NICE and the British National Health Service.
    Pearson SD; Rawlins MD
    JAMA; 2005 Nov; 294(20):2618-22. PubMed ID: 16304076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NICE appraisals should be everybody's business.
    Wells J; Cheong-Leen C
    BMJ; 2007 May; 334(7600):936-8. PubMed ID: 17478847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Michael Rawlins: doing the NICE thing. Interview by Kelly Morris.
    Rawlins M
    Lancet; 2009 Apr; 373(9672):1331. PubMed ID: 19376438
    [No Abstract]   [Full Text] [Related]  

  • 10. Has NICE been nice to cancer?
    Summerhayes M; Catchpole P
    Eur J Cancer; 2006 Nov; 42(17):2881-6. PubMed ID: 17070032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug assessment: UK style.
    Drug Ther Bull; 2013 Dec; 51(12):141-4. PubMed ID: 24336496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. National Clinical Guideline Centre cost-effectiveness assessment for the National Institute for Health and Clinical Excellence.
    Wonderling D; Sawyer L; Fenu E; Lovibond K; Laramée P
    Ann Intern Med; 2011 Jun; 154(11):758-65. PubMed ID: 21646559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative effectiveness review within the U.K.'s National Institute for Health and Clinical Excellence.
    Chalkidou K
    Issue Brief (Commonw Fund); 2009 Jul; 59():1-12. PubMed ID: 19639713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of the difference in results of economic submissions to the National Institute of Clinical Excellence by manufacturers and assessment groups.
    Chauhan D; Miners AH; Fischer AJ
    Int J Technol Assess Health Care; 2007; 23(1):96-100. PubMed ID: 17234022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NICE: mostly a bad idea.
    Leaman A
    Emerg Med J; 2009 Sep; 26(9):627-8. PubMed ID: 19700572
    [No Abstract]   [Full Text] [Related]  

  • 17. Sir Michael Rawlins on being NICE--and fair--about drug development and availability. Interview by Daniel Clarke.
    Rawlins SM
    Drug Discov Today; 2005 Mar; 10(6):383-6. PubMed ID: 15808816
    [No Abstract]   [Full Text] [Related]  

  • 18. A Review of NICE Methods and Processes Across Health Technology Assessment Programmes: Why the Differences and What is the Impact?
    Cowles E; Marsden G; Cole A; Devlin N
    Appl Health Econ Health Policy; 2017 Aug; 15(4):469-477. PubMed ID: 28130691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The National Institute for Health and Clinical Excellence and its role in assessing the value of new cancer treatments in England and Wales.
    Trowman R; Chung H; Longson C; Littlejohns P; Clark P
    Clin Cancer Res; 2011 Aug; 17(15):4930-5. PubMed ID: 21791636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Working with NICE.
    Adams C
    J Fam Health Care; 2007; 17(4):113-4. PubMed ID: 17824208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.